Stephane Bancel Net Worth

The estimated Net Worth of Stephane Bancel is at least $1.32 Milliarde dollars as of 14 February 2024. Mr. Bancel owns over 26,351 units of Moderna Inc stock worth over $434,142,410 and over the last 8 years he sold MRNA stock worth over $879,528,523. In addition, he makes $8,948,210 as Chief Executive Officer und Director at Moderna Inc.

Mr. Bancel MRNA stock SEC Form 4 insiders trading

Stephane has made over 263 trades of the Moderna Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 26,351 units of MRNA stock worth $2,342,077 on 14 February 2024.

The largest trade he's ever made was selling 90,000 units of Moderna Inc stock on 28 December 2022 worth over $16,056,000. On average, Stephane trades about 29,345 units every 6 days since 2016. As of 14 February 2024 he still owns at least 5,460,224 units of Moderna Inc stock.

You can see the complete history of Mr. Bancel stock trades at the bottom of the page.

Stephane Bancel biography

Stephane Bancel serves as Chief Executive Officer, Director of the Company. Before joining the Company, Mr. Bancel has served as our Chief Executive Officer since October 2011 and a member of our board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA (Euronext: BIM). From July 2000 to March 2006, he served in various roles at Eli Lilly and Company (NYSE: LLY), including as Managing Director, Belgium, and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Eli Lilly and Company, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux. Mr. Bancel currently serves on the board of directors of Qiagen N.V. (NYSE: QGEN) and previously served on the boards of directors of BG Medicine, Inc. (OTCMKTS: BGMD) and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.

What is the salary of Stephane Bancel?

As the Chief Executive Officer und Director of Moderna Inc, the total compensation of Stephane Bancel at Moderna Inc is $8,948,210. There are no executives at Moderna Inc getting paid more.

What's Stephane Bancel's mailing address?

Stephane's mailing address filed with the SEC is C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Moderna Inc

Over the last 6 years, insiders at Moderna Inc have traded over $2,713,086,305 worth of Moderna Inc stock and bought 52,631 units worth $999,989 . The most active insiders traders include Noubar Afeyan, David M. Rubenstein und Stephane Bancel. On average, Moderna Inc executives and independent directors trade stock every 2 days with the average trade being worth of $2,841,687. The most recent stock trade was executed by Shannon Thyme Klinger on 6 September 2024, trading 1,139 units of MRNA stock currently worth $90,562.

What does Moderna Inc do?

moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a

Complete history of Mr. Bancel stock trades at Syros Pharmaceuticals und Moderna Inc

Moderna Inc executives and stock owners

Moderna Inc executives and other stock owners filed with the SEC include:

• Stephane Bancel,
  Chief Executive Officer, Director
• Stephen Hoge,
  President
• Tal Zvi Zaks,
  Chief Medical Officer
• Juan Andres,
  Chief Technical Operations and Quality Officer
• Stephane Bancel,
  CEO & Director
• Stéphane Bancel,
  CEO & Director
• Dr. Stephen Hoge M.D.,
  Pres
• Dr. Stephen Hoge,
  Pres
• Juan Andres,
  Chief Technical Operations & Quality Officer
• David W. Meline,
  CFO & Principal Accounting Officer
• Francois Nader,
  Non-Executive Independent Director
• Noubar Afeyan,
  Non-Executive Independent Chairman of the Board, Co-Founder
• Israel Ruiz,
  Non-Executive Independent Director
• Robert Langer,
  Non-Executive Independent Director
• Stephen Berenson,
  Non-Executive Independent Director
• Paul Sagan,
  Non-Executive Independent Director
• Dr. Noubar B. Afeyan Ph.D.,
  Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board
• Elizabeth Tallett,
  Director
• Ray Jordan,
  Chief Corporate Affairs Officer
• Marcello Damiani,
  Chief Digital and Operational Excellence Officer
• Lori Henderson,
  General Counsel, Company Secretary
• Tracey Franklin,
  Chief Human Resource Officer
• David Meline,
  Chief Financial Officer
• Colleen Hussey,
  Sr. Mang. of Corp. Communications
• Shannon Thyme Klinger,
  Chief Legal Officer & Corp. Sec.
• Lori M. Henderson J.D., Esq.,
  Gen. Counsel & Corp. Sec.
• Lavina Talukdar CFA,
  Sr. VP & Head of Investor Relations
• Dr. Melissa J. Moore,
  Chief Scientific Officer & Member of Scientific Advisory Board
• Dr. John V. W. Reynders,
  Chief Information Officer
• Lorence H. Kim,
  Chief Financial Officer
• Elizabeth G Nabel,
  Director
• Noubar Flagship Ventures Fu...,
  
• Shannon Thyme Klinger,
  Chief Legal Officer
• Jennifer Ling Lee,
  Chief Accounting Officer
• Sandra Horning,
  Director
• Peter Barton Hutt,
  Director
• Moncef Slaoui,
  Director
• Ventures Fund Iv General Pa...,
  
• Edwin M Jr Kania,
  10% owner
• Ventures Fund Iv General Pa...,
  
• Goff Corinne Le,
  Chief Commercial Officer
• Paul Burton,
  Chief Medical Officer
• James M Mock,
  Chief Financial Officer
• Arpa Garay,
  Chief Commercial Officer
• David M. Rubenstein,
  Director